Researchers have identified a promising pathway in the amylin hormone, which is released alongside insulin in the pancreas and helps regulate hunger and fullness. Targeting the amylin pathway could provide an additional biological lever for treating obesity and Type 2 diabetes, either as a standalone treatment or layered on top of existing drugs.

Eli Lilly has made significant strides in this area with its experimental amylin-targeting drug eloralintide. In a recent Phase 2 trial, patients with obesity and Type 2 diabetes who received the highest-dose combination of eloralintide and tirzepatide showed substantial weight loss compared to those taking only a high dose of tirzepatide.

The results of this trial are encouraging, especially considering that the patients receiving the combined treatment lost an average of nearly one-quarter of their body weight over 48 weeks. These findings suggest that targeting the amylin pathway could be a valuable strategy in the fight against obesity and Type 2 diabetes.

Researchers are hailing recent findings as significant breakthroughs in the fight against obesity and Type 2 diabetes. These studies suggest that targeting the amylin pathway could be a valuable strategy in this fight.

Pharmaceutical companies Lilly and Novo are investing heavily in developing treatments that target amylin, a hormone involved in glucose regulation. Lilly's eloralintide is being developed both as a standalone treatment and as part of a combination therapy with another medication.

Analysts predict significant revenue growth for Lilly's eloralintide products by 2035, with Leerink Partners' David Risinger forecasting $23.2 billion in annual sales. He expects the standalone drug to hit the market first in 2029, followed by the combo treatment in 2030.

Risinger notes that millions of people have tried GLP-1 therapies and failed due to efficacy or tolerability issues. This large patient pool is seen as a major opportunity for Lilly's amylin analog, which could offer a new treatment alternative both as a monotherapy and combination therapy.

Lilly's cardiometabolic health team is aware that patients may not achieve satisfactory weight loss from GLP-1 receptor agonists like tirzepatide on their own. This realization has led to a focus on combination therapies as a potential solution.

Combination therapy offers an opportunity for patients who have plateaued in their weight loss while taking tirzepatide alone. By adding an amylin analog, Lilly hopes to provide a more effective treatment option.

However, there are still challenges that need to be addressed before the combo regimen can be considered a viable alternative. The data from the Phase 2 study is based on a relatively small patient pool, and the results will need to be confirmed in larger-scale Phase 3 trials later this year.

One of the key concerns surrounding the combination therapy is tolerability - how well patients are able to stick with the treatment without experiencing adverse side effects. In the trial, between 10.8% and 27% of patients discontinued treatment due to side effects, depending on the dose.

The high rate of discontinuation among patients taking both drugs has raised concerns about the therapy's overall effectiveness. "A therapy is only effective if patients can remain on it," said Dr. Bikman, highlighting the importance of tolerability in Phase 3 trials.

Novo Nordisk is also pursuing amylin-based treatments as part of its obesity drug development strategy, mirroring Eli Lilly's efforts. The Danish company has been working on an experimental amylin-based drug called cagrilintide, which has shown significant weight loss results in a late-stage trial.

In combination with semaglutide, another popular diabetes and obesity treatment, cagrilintide produces even more substantial weight loss, according to clinical studies. This dual-therapy approach is expected to hit the market early next year, followed by standalone cagrilintide and a higher-dose version of the combined therapy in 2028.

Novo Nordisk is also developing another amylin-based treatment called zenagamtide, which targets both GLP-1 and amylin receptors. This single molecule has shown promising Phase 2 results earlier this year, with Novo testing it as both a once-weekly injection and a daily oral tablet.

The Danish company's approach to developing long-acting amylin therapies seeks to address the limitations of earlier treatments that required multiple injections per day. These new drugs are designed to mimic the hormone in a sustained way, allowing for less frequent dosing.

New therapies like cagrilintide and zenagamtide aim to provide more convenient and effective treatment options for people with obesity and diabetes.

Researchers are exploring new ways to tackle obesity and related conditions by targeting multiple biological pathways simultaneously. This multi-pronged approach aims to produce more significant weight loss and metabolic benefits than single-pathway treatments can achieve on their own.

The amylin pathway, in particular, shows promise as a complement to GLP-1-based therapies. By acting through an entirely different mechanism, amylin helps regulate fullness, suppress appetite, and slow gastric emptying. This distinct approach may offer a more effective treatment option for individuals struggling with obesity and diabetes.

Novo's CagriSema has demonstrated impressive results in this regard. According to new data from the company, this treatment not only promotes weight loss but also reduces "food noise", persistent thoughts about food, in individuals with obesity or those who are overweight.

A year-long study using functional magnetic resonance imaging (fMRI) revealed that CagriSema altered brain activity in areas linked to cravings, pleasure, and self-control. This change is associated with improved quality of life, as noted by Martin Holst Lange, Novo's chief scientific officer.

These findings suggest that targeting multiple hormone pathways can have far-reaching benefits beyond physical changes alone. The obesity drug race is shifting towards this more comprehensive approach, which may hold the key to developing more effective treatments for individuals struggling with these conditions.

The latest wave of experimental obesity drugs is incorporating amylin into its formula, building on the success of earlier treatments like tirzepatide that combine GLP-1 with other hormones. Lilly's retatrutide has shown impressive results in clinical trials, including significant reductions in liver fat, triglycerides and fasting insulin.

The introduction of combination amylin drugs is aimed at providing patients with a range of treatment options tailored to their specific needs. While it remains to be seen whether these new treatments will outperform existing ones like tirzepatide, they are all working towards the same goal: offering individuals a more personalized approach to managing obesity and related conditions.

CNBC: https://www.cnbc.com/2026/10/02/lilly-novo-amylin-obesity-drugs.html

The amendment, which came into effect on Wednesday, reduces the penalty for first-time offenders from imprisonment to fines ranging from 10,000 to 20,000 Tunisian dinars ($3,370 to $6,740).

This change is a significant shift from the original law, which imposed a five-year prison sentence on those convicted of spreading "false news or related violations. Repeat offenders may still face jail time.

Rights and media freedom advocates have long criticized Decree 54, arguing that it has been used to silence President Kais Saied's opposition, activists, and reporters.

The penalties for spreading false information under Decree 54 were severe, with fines and prison sentences imposed on individuals who shared doctored content or made untrue allegations to incite hatred or damage someone's reputation.

Those targeting public officials or people of equivalent status faced even harsher punishments, including up to a decade in prison and a fine of over $32,000. Repeat offenders were also subject to additional penalties, with six months behind bars and a $16,000 fine for those who continued to spread false information.

The decree's provisions had significant implications for free speech in Tunisia, with critics arguing that it was used to silence opposition voices and restrict civic space. The law was seen as a potent tool of oppression by international organisations concerned with press freedom.

Tunisian officials have faced criticism from rights groups and former government figures who argue that the decree has been misused to suppress dissent and limit free expression in the country.

The Tunisian government's crackdown on dissent has been a contentious issue since President Kais Saied initiated a severe crackdown against opposition parties, including Ennahdha, which was once a leading force in the country's politics.

Under Saied's rule, hundreds of journalists, bloggers, and activists have faced prosecution for speaking out against the government. The National Syndicate of Tunisian Journalists has documented numerous cases of individuals being tried under Decree 54, with many facing lengthy prison sentences or even death.

In recent years, the number of prosecutions has continued to rise, with at least six journalists targeted under the decree between April 2025 and April 2026. One notable example is prominent lawyer and columnist Sonia Dahmani, who was sentenced to two years in prison for criticizing conditions in Tunisian prisons during a radio interview this May.

Dahmani's case is not an isolated incident; she has been charged under Decree 54 on multiple occasions, with five separate cases relating to her media appearances. Her previous conviction in 2024 for criticizing Saied's policies resulted in an 18-month prison sentence.

The international community has also weighed in on the issue, with organizations like Amnesty International and Human Rights Watch condemning Decree 54 as a tool for suppressing fundamental freedoms. Even the European Parliament has called for its repeal, highlighting concerns about the decree's impact on free speech and democracy.

The move to soften Tunisia's false news penalty has sparked debate about the country's democratic trajectory since President Saied took office in 2011. Critics argue that his actions have undermined progress made during the Arab Spring revolution.

Saied's decision to suspend parliament and dismiss the government in 2021 marked a significant shift away from democratic norms, with many viewing it as an attempt to consolidate power. The subsequent introduction of a new constitution in 2022 cemented these changes, despite widespread criticism that it represented an erosion of Tunisia's democratic institutions.

The president has maintained that his actions are necessary to address years of disorder and alleged corruption, but his critics see it as a thinly veiled attempt to suppress dissent and opposition. Amidst growing concerns about political repression, Saied won re-election in 2024 with a landslide victory, albeit on a low voter turnout.

Tunisia's largest labour union has joined forces with civil society groups to organize a nationwide march against what they see as restrictions on civil liberties, highlighting the deep-seated disillusionment among citizens with their government.

Tunisia has witnessed a surge in protests over the past year, as citizens express their discontent with government actions. Demonstrations against abuses of power, democratic backsliding, and deteriorating living standards have become increasingly common. In June, hundreds of protesters gathered in Tunis to demand press freedom and the release of detained critics.

The mobilization of civil society has been credited with forcing the government to reconsider its stance on certain issues. The suspension of parliament by President Saied five years ago is still a contentious topic, with thousands gathering in July to urge him to step down. This public pressure has also led to international attention being focused on Tunisia's democratic situation.

The country has faced mounting criticism from abroad, particularly from the United States. A US House of Representatives member, Joe Wilson, stated that he would continue to push for a bill imposing sanctions on Saied and those close to him due to their anti-democratic policies. This external pressure may have contributed to the government's decision to soften its stance on certain issues.

Critics argue that the amended penalties do not go far enough in addressing concerns about freedom of speech under Saied's government. The International Commission of Jurists has described the change as a positive development, but notes that more is needed, including an end to all abusive prosecutions and the release of those detained arbitrarily.

The revised penalty for spreading false news" in Tunisia has been reduced, but its underlying repressive nature remains intact. According to Abdessalem, this change was made to soften the image of President Saied's government, which has come under scrutiny due to its handling of trials, arrests, and use of arbitrary decrees.

The move has been met with skepticism by civil society groups and journalists' unions, who had demanded that Decree 54 be abolished altogether. They argue that journalists should be held accountable under the press freedom law passed in 2011, which balances individual rights with professional responsibilities. Despite proposals for a broader overhaul of media laws since 2024, these efforts have been ignored by parliament.

Al Jazeera: https://www.aljazeera.com/news/2026/10/2/tunisia-softens-its-false-news-penalty-what-really-changed-and-why-now?traffic_source=rss

The TCL QM-series of Mini LED TVs, which compete with Samsung's M-series, use advanced backlighting technology that enhances image quality and delivers high dynamic range (HDR) on LCD-LED displays. However, without clear guidelines for what "Mini LED means, manufacturers are free to define the term as they see fit.

In a lawsuit filed in California in late August, TCL accused Samsung of using fraud to promote its M70H, M80H, and M90H TVs as Mini LED sets. The complaint alleges that these models are actually rebranded versions of Samsung's entry-level Crystal UHD line, which lacks the advanced backlighting capabilities associated with true Mini LED technology.

The lawsuit claims that Samsung's M-series TVs do not have backlights capable of full array local dimming (FALD), a key feature of high-end LCD-LED displays. FALD involves grouping multiple LEDs into zones, each with adjustable brightness levels to enhance contrast and deliver superior image quality.

A spokesperson for Samsung declined to comment on specific claims in the lawsuit, instead stating that the company intends to vigorously defend against TCL's allegations. The dispute highlights a pressing issue for consumers: without standard definitions for Mini LED technology, manufacturers can use the term to describe their products with varying degrees of accuracy.

TCL argues that true Mini LED displays require advanced backlighting capabilities, including FALD, which is essential for delivering high-quality HDR on LCD-LED screens. The company's lawsuit seeks to establish clear guidelines for what constitutes a Mini LED display and prevent manufacturers from misusing the term.

The outcome of this lawsuit could have significant implications for the TV industry, with potential consequences for consumers who rely on accurate product labeling when making purchasing decisions. As the case unfolds, it will be interesting to see how TCL's claims are received by Samsung and the wider industry.

The debate over Samsung's use of the term Mini LED on its M-series TVs has taken a interesting turn as TCL questions the accuracy of this labeling.

A closer look at the specifications for these TVs reveals that they employ Supreme Mini LED Dimming, which is described in the product pages' fine print as software-based technology. This distinction is crucial, as it highlights a key difference between Samsung's M-series and other TVs on the market that genuinely boast mini-LED backlighting.

In contrast to true mini-LED displays, which use individually addressable LEDs to create zones of varying brightness, Samsung's M-series relies on software analysis to determine optimal brightness levels for each frame. This approach may not be as effective in scenes prone to blooming artifacts, but it can still provide decent image quality with fewer LEDs or dimming zones.

Industry experts agree that true mini-LED displays require a specific hardware configuration, including a 2D array of LEDs uniformly distributed across the entire display area. Without this setup, software-based solutions like Samsung's simply don't qualify as genuine mini-LED technology.

Guillaume Chansin, associate director of displays and XR at Counterpoint Research, acknowledges that software plays an important role in optimizing image quality, but notes that it can never fully replace a well-designed hardware solution.

Eric Virey, principal displays analyst at Yole Intelligence, takes a more stringent view, insisting that FALD is fundamentally a hardware feature. Without the necessary 2D array of LEDs and accompanying algorithm to reduce blooming, software-based solutions are merely Mini LED dimming in name only.

The nuances of this debate will undoubtedly be closely watched by both industry insiders and consumers seeking clarity on what constitutes genuine mini-LED technology.

As TCL continues to push back against Samsung's labeling, it remains to be seen how the wider industry will respond. Will other manufacturers follow suit, or will they maintain their own interpretations of what constitutes a true mini-LED display?

The debate over what constitutes a true mini-LED display has sparked controversy in the industry, with TCL questioning Samsung's use of the term on its M-series TVs.

Industry experts agree that a key feature of mini-LED displays is local dimming, also known as full-array local dimming (FALD). This technology allows for more precise control over backlight zones, enhancing contrast and image quality.

Leading industry researchers concur with this assessment. I think that is broadly agreed across the industry that FALD is a key and mandatory feature in Mini LED backlights, said one expert.

The importance of local dimming in mini-LED displays is also reflected on Samsung's own website, which describes the technology as an advanced backlighting display system using tiny LEDs for precise control through local dimming zones.

However, TCL has argued that Samsung's M-series TVs do not support FALD. The company claims to have disassembled these sets and found that they lack the necessary LED control chip and circuitry required for local dimming.

The absence of FALD is just one issue with Samsung's M-series TVs. Another concern is whether they actually use mini-LEDs, which are typically defined as LEDs measuring between 0.1 mm to 0.3 mm in size.

Industry standards for what constitutes a mini-LED vary, and some sources refer to LEDs larger than 0.2 mm or even 3 mm as traditional LEDs. TCL's lawsuit claims that the LEDs used in Samsung's M-series TVs are significantly larger at 0.5 mm, raising questions about their classification as mini-LEDs.

The question of what constitutes a Mini LED display has been raised by TCL's lawsuit against Samsung, which claims that the LEDs used in Samsung's M-series TVs are significantly larger than those found in true mini-LED displays.

To support its claim, TCL points out that Samsung's M-series TVs have only a few dozen LEDs arranged on two aluminum strips, rather than thousands of tiny LEDs that are characteristic of genuine mini-LED technology. This arrangement is also visible in teardown videos from YouTube channel AP Tech, which show the backlight of an M-series TV consisting of just two rows of LEDs.

The lack of clear standards for what constitutes a Mini LED display has led to confusion among consumers and created a gray area where manufacturers can set their own definitions. The industry has not established any guidelines or regulations to define how many LED zones or mini-LEDs a display needs to qualify as a Mini LED, leaving shoppers to navigate unclear marketing claims.

Industry experts say that this lack of clarity is due in part to the absence of organizations with authority to establish and enforce standards for the display panel industry. As a result, TV brands have historically exploited this lack of clear guidelines to be more creative in their marketing, often using terms like Mini LED to describe displays that may not actually meet the criteria.

Some experts believe that TCL's claims raise important questions about the entire industry's use of the term Mini LED. Virey notes that while enthusiasts may enjoy digging into the technical details of backlight technology, most consumers simply care about performance.

The performance of Samsung's M-series TVs has been mixed in reviews. RTINGS found that the M80H had low contrast, with dark scenes looking washed out in a dark room. The review also noted that HDR content mastered at 600 or 1,000 nits cut off rapidly at the TV's peak brightness.

The debate over what constitutes a Mini LED display highlights the ongoing challenge of defining and regulating emerging technologies in the display panel industry. As Virey notes, creating standards for these technologies can be a complex process that may lead to an endless cycle of innovation and marketing claims.

The contrast ratio achieved by TCL's budget QM6K TV after calibration was 118:059:1, significantly lower than Samsung's Mini LED Neo QLED QN80H, which reached a contrast of 80,000:1 according to RTINGs.

A video comparison between M-series TVs and those with Full Array Local Dimming (FALD) technology shows how dimming works differently in each case. This highlights the importance of local dimming in achieving high contrast ratios.

TCL's QM6K TV has some drawbacks despite its impressive contrast ratio. Its HDR performance is reportedly lacking, which may be a concern for consumers who want to enjoy high dynamic range content on their TVs.

According to RTINGs' review, the QM6K TV looks good in a dark room thanks to its high contrast ratio and great black uniformity, but it falters in other areas. The reviewer notes that the TV's HDR brightness is mediocre at best, which can detract from the viewing experience.

The fact that TCL has an obvious stake in challenging Samsung's marketing claims raises questions about the motivations behind this criticism. However, the underlying issue remains: what should consumers expect when a TV is marketed as Mini LED?

A key distinction between different types of Mini LED TVs is how they use local dimming to improve contrast and HDR performance. While smaller LEDs may be used in some Mini LED TVs, it's not just the size of these LEDs that matters - it's how they're used to deliver improved picture quality.

TCL's own budget line of Mini LED TVs can disappoint in areas where the technology should have an advantage, such as HDR support. Compared to Samsung's more expensive Mini LED TVs, TCL's M-series has worse HDR performance and black levels, making it harder to use in a dark room according to RTINGs' testing.

The debate over what constitutes a true Mini LED TV with local dimming highlights the complexity of marketing claims in the tech industry. As new technologies emerge, manufacturers must balance innovation with consumer expectations, leading to a cycle of innovation and marketing claims that can be difficult to navigate.

Consumers navigating the TV market may find themselves in a confusing situation due to the proliferation of marketing terms such as Mini LED" and "QLED". These labels are often used without providing clear information about the actual performance capabilities of the TVs.

Ultimately, it is essential for shoppers to look beyond marketing labels and focus on more reliable indicators of a TV's quality, including comparative pricing and independent testing results.

Ars Technica: https://arstechnica.com/gadgets/2026/10/tcl-is-right-to-question-samsungs-use-of-the-term-mini-led/

The complaint centers around the fact that both songs "share musical features" that are so striking they cannot have arisen by coincidence alone, according to the publishers of Withers' catalogue. They claim that a musicologist hired to review the two songs concluded that the works contain substantial similarities, including repeated copying of the melody from Just The Two of Us.

The lawsuit names Olivia Dean's record label Capitol Records, parent company Universal Music Group and her publishing companies as defendants, but does not seek damages from the singer herself or her co-writers Bastian Langebæk and Max Wolfgang.

A review of the two songs by a musicologist hired by Withers' publishers found that they contain substantial similarities in their melodies, with repeated copying of the iconic tune from Just The Two of Us being one key similarity noted.

The lawsuit filed by Mattie Music Group against Olivia Dean hinges on proving that she and her co-writers had prior knowledge of Bill Withers' iconic song Just The Two of Us.

To establish plagiarism, the plaintiffs must demonstrate that Dean's team was exposed to the original composition before writing I've Seen It. They argue that the sustained commercial success of Just The Two of Us, including decades of radio play, would have provided a reasonable opportunity for Dean and her co-writers to have encountered the song.

The commercial success of Just The Two of Us is undeniable, with the song having achieved widespread recognition and acclaim over the years.

Dean's representatives have yet to respond to the lawsuit, despite multiple requests for comment from both them and their team.

The lawsuit against Olivia Dean has raised questions about her songwriting skills and potential copyright infringement.

Just The Two of Us, a song by Bill Withers, is one of his most famous tracks, having been streamed 246 million times on Spotify alone.

Its chart success in the US was significant, reaching number two in 1981, and it earned Withers a Grammy for best R&B song, a prestigious award that acknowledges outstanding work in the genre.

The track's enduring popularity is evident in its massive play count of over 948 million streams on various platforms.

While Dean has achieved considerable success with her own music, having picked up the best new artist award at this year's Grammys, her album The Art of Loving also reached impressive heights.

The Australian singer-songwriter Olivia Dean has been accused of copying Bill Withers' classic hit Just The Two of Us in her own song.

Dean's version of Just The Two of Us was uploaded to YouTube and features a recognizable rendition of the 1981 original, with some minor adjustments to the melody and tempo. While it is unclear whether the changes are sufficient to avoid copyright infringement claims, the similarities between the two songs are undeniable.

The comparison raises questions about originality in music composition and the fine line between homage and plagiarism.

BBC News Entertainment: https://www.bbc.co.uk/news/articles/c933k3gk72x6o?at_medium=RSS&at_campaign=rss

The company believes that settling the lawsuit will enable management to focus on executing its business objectives without the distraction and costs associated with prolonged litigation. In a regulatory filing, Lyft stated that it made this decision in order to move forward from the controversy and concentrate on its core operations. By doing so, the company aims to maintain momentum in an increasingly competitive market.

The lawsuit was initiated by the California Labor Commissioner's Office in August 2020, claiming that Lyft treated drivers as independent contractors rather than employees under state law at the time. This classification resulted in drivers being denied minimum wage and overtime pay, among other benefits typically reserved for employees.

The settlement comes after a lengthy investigation into Lyft's labor practices, with allegations of denying drivers paid sick leave and timely wage payments. California Labor Commissioner Lilia García-Brower praised the workers who came forward to speak out against the company, stating that their voices made this outcome possible.

A significant milestone has been reached in the ongoing debate over worker classification in California's gig economy. The state Labor Commissioner's Office (LCO) has announced a settlement with Lyft, requiring the company to pay $272.5 million over alleged violations of labor laws.

The period covered by the settlement spans from April 6, 2016 to December 15, 2020, a time when California was grappling with how to classify workers in the rapidly growing gig economy. This classification issue has been a contentious one, with some arguing that drivers should be considered independent contractors and others advocating for them to be treated as employees.

The settlement comes after voters passed Proposition 22 in 2020, which exempted companies like Lyft from Assembly Bill 5 (AB 5), a state law requiring gig workers to be classified as employees. Despite AB 5 taking effect, Lyft and other companies continued to classify their drivers as contractors, leading to legal action.

The LCO has coordinated lawsuits with the California Attorney General's office and city attorneys from Los Angeles, San Diego, and San Francisco. Private actions have also been filed under California's Private Attorneys General Act. Uber still faces an LCO lawsuit making similar allegations against the company.

Lyft has agreed to settle a lawsuit filed by drivers who claimed they were misclassified as independent contractors rather than employees.

The lawsuit alleged that Lyft had failed to provide its drivers with basic benefits such as health insurance and paid time off, despite operating in multiple states where such benefits are required by law. The settlement is reportedly worth $272.5 million and will be distributed among the affected drivers. This move comes after a similar lawsuit was filed against Uber.

The outcome of this case may have significant implications for the gig economy as a whole, with many companies relying on independent contractors to operate their services. While Lyft has agreed to settle the lawsuit, it still faces an LCO lawsuit making similar allegations against the company.

TechCrunch: https://techcrunch.com/2026/10/01/lyft-is-paying-272-5m-to-settle-lawsuit-over-how-it-classified-drivers/

Governor Bill Lee expressed disappointment over the incident, describing it as one of the state's most critical responsibilities. He announced that an independent review would be conducted to examine what went wrong during the attempted execution. This review is expected to be thorough and time-consuming.

Tennessee prison officials attempted to administer two lethal doses of pentobarbital to Christa Pike, but she survived and was taken to hospital for treatment. Her medical condition remains unclear at this point in time. The incident has sparked concerns about the state's ability to carry out executions safely and humanely.

Christa Pike, a 50-year-old woman, was sentenced to death in 1996 for her role in the murder of Colleen Slemmer when she was just 18 years old. This would have been Tennessee's first female execution in over two centuries if the lethal injection had succeeded.

The decision to halt all executions in Tennessee comes as a surprise, coinciding with plans to carry out the execution of Gary Sutton on 3 December. This development is likely to raise questions about the state's lethal injection protocol.

Pike's lawyers have expressed concern that their client needed immediate medical attention after the botched execution attempt, highlighting the need for life-saving measures. The Tennessee Department of Correction has defended its handling of the case, stating that it followed established protocols approved by the attorney general's office.

The department claims to have adhered strictly to the state's lawful and established execution protocol, which does not allow for additional procedures beyond what was carried out during Pike's attempted execution. However, court filings reveal that two doses of pentobarbital were administered, but still failed to result in a successful lethal injection.

As investigators look into the circumstances surrounding Pike's near-execution, her lawyers are calling for an end to her "unnecessary agony. The state's attorney general has agreed with the decision to launch an investigation, emphasizing the need to determine what went wrong during the execution attempt.

The botched execution of Christa Pike has left many questioning the state's handling of capital punishment. May Martinez, whose son was a victim of Pike, expressed her disappointment at the failed attempt, describing it as a mess. Her words reflect the sense of frustration and disillusionment that has been building among those who advocate for swift justice.

The incident has also sparked a heated debate among politicians in Tennessee. Republican Senator Marsha Blackburn called the situation tragic and suggested that the electric chair be reinstated as an alternative method of execution. However, her opponent, Democrat Jerri Green, took issue with this proposal, labeling it one of the most cruel forms of capital punishment".

Green's criticism highlights the deep divide in opinions on the matter, with some advocating for a more humane approach and others pushing for a return to traditional methods. The recent failure is not an isolated incident; it marks the second time in 2026 that Tennessee officials have struggled to carry out an execution.

The state will now conduct a thorough review of what went wrong during the execution attempt, with the aim of preventing similar incidents in the future.

BBC News World: https://www.bbc.co.uk/news/articles/cmn4540d4z87o?at_medium=RSS&at_campaign=rss